| 1． |
Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left- ventricular mass in the Framingham-heart-study. N Engl J Med 1990; 322:1561-6.
|
| 2． |
Lorell BH, Carabello BA. Left ventricular hypertrophy- pathogenesis, detection, and prognosis. Circulation 2000; 102:470-9.
|
| 3． |
Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 1999; 341:1276-83.
|
| 4． |
Harada E, Nakagawa O, Yoshimura M, et al. Effect of interleukin-1β on cardiac hypertrophy and production of natriuretic peptides in rat cardiocyte culture. J Mol Cell Cardiol 1999; 31:1997-2006.
|
| 5． |
Sakata Y, Yamamoto K, Mano T, et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 2004; 109:2143-9.
|
|
6．Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005; 54:2460-70.
|
|
7．Irukayama-Tomobe Y, Miyauchi T, Sakai S, et al. Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway. Circulation 2004; 109:904-10..
|
|
8．Planavila A, Rodriguez-Calvo R, Jove M, et al. Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res 2005; 65:832-41.
|
| 9． |
Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 105:868-73.
|
| 10 |
．Nishikawa H, Miura S, Zhang B, et al. Statins induce the regression of left ventricular mass in patients with angina. Circ J 2004; 68:121-5.
|
| 11 |
．Simpson P, McGrath A, Savion S. Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines. Circ Res 1982; 51:787-801.
|
| 12 |
．Simpson P, Savion S. Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyo- cardial cells. Circ Res 1982; 50:101-16.
|
| 13 |
．Thaik CM, Calderone A, Takahashi N, et al. Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest 1995; 96:1093-9.
|
| 14 |
．Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001; 108:1429-37.
|
|
15．Porter KE, Turner NA, O’Regan DJ. Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovasc Res 2004; 61:745-55.
|
| 16 |
．Frey N, Katus HA, Olson EN, et al. Hypertrophy of the heart: a new therapeutic target? Circulation 2004; 109:1580-9.
|
| 17 |
．Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001; 104:317-24.
|
| 18 |
．Ye P, Fang H, Zhou X, et al. Effect of peroxisome proliferator-activated receptor activators on tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Chin Med J Sci 2004; 19:243-7.
|
| 19 |
．Ding G, Cheng L, Qin Q, et al. PPAR delta modulates lipopolysaccharide-induced TNF alpha inflammation signaling in cultured cardiomyocytes. J Mol Cell Cardiol 2006; 40:821-8.
|
| 20 |
．Zhang H, Shao Z, Alibin CP, et al. Liganded peroxisome proliferator-activated receptors (PPARs) preserve nuclear histone deacetylase 5 levels in endothelin-treated Sprague-Dawley rat cardiac myocytes. PLoS One 2014; 9:e115258.
|
| 21 |
．Paumelle R, Staels B. Cross-talk between statins and PPAR alpha in cardiovascular diseases: clinical evidence and basic mechanisms. Trends Cardiovasc Med 2008; 18:73-8.
|
| 22 |
．Lee TM, Chou TF, Tsai CH. Association of pravastatin and left ventricular mass in hypercholesterolemic patients: role of 8-iso-prostaglandin F2a formation. J Cardiovasc Pharmacol 2002; 40:868-74.
|
| 23 |
．Inoue I, Goto S, Mizotani K, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyc- looxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary endothelial cells. Life Sci 2000; 67:863-76.
|
| 24 |
．Desjardins F, Sekkali B, Verreth W, et al. Rosuvastatin increases vascular endothelial PPAR-γ expression and corrects blood pressure variability in obese dyslipidaemic mice. Eur Heart J 2008; 29:128-37.
|
